← All trials
NCT07042594
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 26, 2025
- Primary completion
- Jun 30, 2026
- Completion date
- Sep 30, 2026
- First posted
- Jun 29, 2025
- Last posted
- Sep 30, 2025
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Ribo Life Science Co. Ltd.Lead sponsor
- Suzhou Ribo Life Science Co. Ltd.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.